Earnings Feed
Start Free
Home/Filings/3/0000899243-19-026822
3//SEC Filing

Clarus IV-A, L.P. 3

Accession 0000899243-19-026822

CIK 0001563577other
View on SEC.govCompany Profile

Filed

Nov 5, 7:00 PM ET

Accepted

Nov 6, 5:34 PM ET

Size

18.7 KB

Accession

0000899243-19-026822

Insider Transaction Report

Form 3
Period: 2019-11-06
Galera Therapeutics, Inc.GRTX
Clarus IV-A, L.P.
10% Owner
Holdings

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (1,552,035 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (561,385 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (2,334,966 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (2,807,372 underlying)
Clarus IV GP L.P.
10% Owner
Holdings

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (2,334,966 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (2,807,372 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (1,552,035 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (561,385 underlying)
Clarus IV-B, L.P.
10% Owner
Holdings

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (2,334,966 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (2,807,372 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (1,552,035 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (561,385 underlying)
Clarus IV-C, L.P.
10% Owner
Holdings

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (2,334,966 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (561,385 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (1,552,035 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (2,807,372 underlying)
Clarus IV-D, L.P.
10% Owner
Holdings

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (1,552,035 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (561,385 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (2,334,966 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: See Footnotes)
    → Common Stock (2,807,372 underlying)
Footnotes (9)
  • [F1]These shares of the Issuer's Series C redeemable convertible preferred stock ("Redeemable Convertible Preferred Stock") are convertible into shares of the Issuer's common stock ("Common Stock") on a 0.197763-for-one basis at the holder's election and have no expiration date. The Redeemable Convertible Preferred Stock will automatically convert into Common Stock upon the closing of the Issuer's initial public offering.
  • [F2]These securities are held directly by Clarus IV-A, L.P.
  • [F3]These securities are held directly by Clarus IV-B, L.P.
  • [F4]These securities are held directly by Clarus IV-C, L.P.
  • [F5]These securities are held directly by Clarus IV-D, L.P. (collectively, with Clarus IV-A, L.P., Clarus IV-B, L.P. and Clarus IV-C, L.P., the "Clarus Funds").
  • [F6]The general partner of each of the Clarus Funds is Clarus IV GP, L.P. The general partner of Clarus IV GP, L.P. is Blackstone Clarus GP L.P. The general partner of Blackstone Clarus GP L.P. is Blackstone Clarus GP L.L.C. The sole member of Blackstone Clarus GP L.L.C. is Blackstone Holdings II L.P. The general partner of Blackstone Holdings II L.P. is Blackstone Holdings I/II GP L.L.C. The sole member of Blackstone Holdings I/II GP L.L.C. is The Blackstone Group Inc. The sole holder of the Class C common stock of The Blackstone Group Inc. is Blackstone Group Management L.L.C. Blackstone Group Management L.L.C. is wholly-owned by Blackstone's senior managing directors and controlled by its founder, Stephen A. Schwarzman.
  • [F7]Due to the limitations of the electronic filing system certain Reporting Persons are filing a separate Form 3.
  • [F8]Information with respect to each of the Reporting Persons is given solely by such Reporting Person, and no Reporting Person has responsibility for the accuracy or completeness of information supplied by another Reporting Person.
  • [F9]Each of such Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the Clarus Funds to the extent of their direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.

Documents

1 file

Issuer

Galera Therapeutics, Inc.

CIK 0001563577

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001700720

Filing Metadata

Form type
3
Filed
Nov 5, 7:00 PM ET
Accepted
Nov 6, 5:34 PM ET
Size
18.7 KB
View on SEC.gov